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tected from a single fecal sample ex-
amined on microscopy (1), infection 
most likely resulted from consump-
tion of infective eggs in the feces of 
a carnivore-defi nitive host. This host 
could have been a translocated domes-
tic dog, thought to be the mechanism 
of recent introduction of E. multilocu-
laris parasites into Sweden (7). It is 
also possible that a European strain of 
the parasite was introduced into North 
America in the last century, when red 
fox from France and Scandinavia were 
introduced (8).
 The possible establishment of a 
European strain in North American 
wildlife, with spillover into domestic 
dogs, may have implications for pub-
lic health and require increased vigi-
lance by medical and veterinary per-
sonnel in the newly endemic region. 
Compared with native North Ameri-
can strains, European strains of E. 
multilocularis appear to have greater 
potential to cause alveolar hydatid dis-
ease (AHD) in humans. These strains 
are emerging worldwide (increasing 
in both prevalence and distribution) as 
a result of changes in landscape, cli-
mate, and wildlife–human interfaces 
(2,9,10). In Europe, human AHD can 
be fatal (defi nite or probable cause of 
death in 23.5% of 119 recent cases) 
and has low cure rates (5% of 408 re-
cent cases) (2). As of 2000, in Europe 
and Asia, the estimated cost per case 
of AHD was US $100,000–$300,000 
(9). Therefore, better understanding of 
the distribution, genetic diversity, and 
pathogenicity of strains of E. multi-
locularis is needed to assess risks and 
mitigate costs for public and veteri-
nary health, as well as to provide evi-
dence for the regulation and screening 
of imported domestic animals and 
translocated wildlife.
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Recognition 
and Diagnosis of 
Cryptococcus 
gattii Infections in 
the United States
To the Editor: An outbreak of 
Cryptococcus gattii cryptococcosis 
has been ongoing in the US Pacifi c 
Northwest (PNW) since 1999 (1–3). In 
contrast to C. neoformans infections, 
which typically cause meningitis 
in HIV-infected persons, outbreak-
associated C. gattii infections occur 
primarily in persons without HIV 
and often cause pneumonia (1–3). 
Sporadic, nonoutbreak-associated C. 
gattii infections often cause meningitis 
and have been reported outside the 
PNW (1–4). The prevalence of both 
types of C. gattii infection in the 
United States is unknown because 
diagnostic practices and awareness 
vary among physicians.
Some reports indicate that 
patients with C. gattii infections 
may respond to treatment more 
slowly and relapse more frequently 
than patients with C. neoformans 
infections and, thus, may require 
more aggressive clinical management 
(5–8). Therefore, differentiation of C. 
gattii from C. neoformans infections 
may be necessary for optimal patient 
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management. However, cryptococcal 
infections are often diagnosed 
by antigen testing, which cannot 
distinguish between C. gattii and C. 
neoformans, and differential agar 
necessary to distinguish species in 
culture (9) is not uniformly used in 
clinical laboratories. In addition to 
possible missed diagnoses caused by 
the atypical manifestation of outbreak-
associated C. gattii, outbreak-
associated and sporadic C. gattii 
infections in the United States are 
likely being misdiagnosed as C. 
neoformans infections.
We conducted a survey of US 
infectious disease physicians to better 
understand the clinical approach to 
diagnosing cryptococcal infections, 
the relative regional frequency 
of C. gattii, and the capacity of 
clinical laboratories to differentiate 
cryptococcal species. To survey 
physicians, we used the Emerging 
Infections Network (EIN), a sentinel 
public health surveillance system of 
infectious disease clinicians that is 
supported by the Centers for Disease 
Control and Prevention and sponsored 
by the Infectious Diseases Society 
of America (10). During February–
March 2011, web-based surveys were 
distributed by email or fax to the 1,342 
EIN members, of whom 792 (59%) 
responded. 
Analysis was restricted to 286 
(36%) respondents (representing 43 
states) who treated a cryptococcosis 
patient during the past year. We 
compared answers from respondents 
in the 4 US census regions (Table; 
online Appendix Figure, wwwnc.cdc.
gov/EID/article/18/1/11-1228-FA1.
htm). Results were analyzed by using 
SAS version 9.2 (SAS Institute Inc., 
Cary, NC).
The approximate number of 
reported physician consults for 
cryptococcosis was similar among 
respondents from all regions 
(Table). More respondents from 
the West (40%), compared with 
the South (21%), Midwest (22%), 
and Northeast (19%), reported 
that >25% of their cryptococcosis 
patients had pneumonia; this fi nding 
may refl ect the higher prevalence 
of outbreak-associated C. gattii 
infections in the West (1–3). The 
percentage of respondents who treated 
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Table. Physician responses, by US region, to a survey about cryptococcosis, February–March 2011* 
Question and responses
No. (%) responding physicians†
Overall,
n = 286 
Northeast,
n = 48 
Midwest, 
n = 63 
South,
n = 113 
West,
n = 62 
No. patients with cryptococcosis seen during the past year      
 1–4 218 (76) 41 (85) 55 (87) 71 (63) 51 (82) 
 5–8 49 (17) 6 (13) 7 (11) 29 (26) 7 (11) 
 9–12 12 (4) 1 (2) 1 (2) 8 (7) 3 (5) 
 >12 7 (2) 0 0 5 (4) 1 (2) 
Percentage of patients with cryptococcal pneumonia, with or without meningitis     
 0–25 213 (75) 39 (81) 49 (78) 89 (79) 36 (59) 
 26–50 33 (12) 1 (2) 6 (10) 13 (12) 13 (21) 
 51–75 8 (3) 1 (2) 1 (2) 4 (4) 2 (3) 
 76–100 31 (11) 7 (15) 7 (11) 7 (6) 10 (16) 
Method used to obtain a diagnosis of cryptococcosis (all that apply)      
 Cryptococcal antigen test 272 (95) 48 (100) 58 (92) 110 (97) 56 (90) 
 Microscopy 95 (33) 16 (33) 13 (21) 42 (37) 24 (39) 
 Culture 210 (73) 33 (69) 50 (79) 82 (73) 45 (73) 
 Histopathology 75 (26) 10 (21) 10 (16) 31 (27) 24 (39) 
  Any combination of tests that does not include culture 76 (27) 15 (31) 13 (21) 31 (27) 17 (27) 
Clinical laboratory routinely or on request can differentiate Cryptococcus 
neoformans from C. gattii‡
131 (66) 20 (67) 28 (68) 48 (64) 35 (66) 
Percentage of cryptococcal infection cases in HIV-uninfected patients      
 0–25 154 (54) 32 (68) 26 (41) 70 (62) 26 (44) 
 26–50 48 (17) 5 (11) 15 (24) 16 (14) 12 (20) 
 51–75 32 (11) 3 (6) 9 (14) 11 (10) 9 (15) 
 76–100 51 (18) 7 (15) 13 (21) 16 (14) 12 (20) 
Diagnosed cryptococcal infections in HIV-uninfected patients with no 
known risk factors for infection during past 5 y
78 (27) 6 (13) 13 (21) 26 (23) 33 (53) 
Considers species of Cryptococcus as a factor of interest in diagnosis or 
when treating a patient
179 (63) 22 (46) 36 (57) 71 (63) 50 (81) 
Considered C. gattii infection as a differential diagnosis for pneumonia in 
a person from the US Pacific Northwest
153 (54) 19 (40) 29 (46) 63 (56) 42 (68) 
Ever treated or consulted on a patient known to have C. gattii infection 38 (13) 5 (10) 3 (5) 3 (3) 27 (44) 
*The survey was conducted by the Emerging Infections Network among physician members; responses are from providers who had seen any patients 
with cryptococcosis during the preceding year. Region is defined by the 4 census regions: Northeast (Connecticut, Maine, Massachusetts, New 
Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont), Midwest (Indiana, Illinois, Iowa, Kansas, Michigan, Minnesota, Missouri, 
Nebraska, North Dakota, Ohio, South Dakota, Wisconsin), South (Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, 
Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia), West (Alaska, Arizona, 
California, Colorado, Hawaii, Idaho, Montana, New Mexico, Nevada, Oregon, Washington, Wyoming). 
†Not all respondents answered all questions.
‡Excludes “don’t know” responses. 
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cryptococcosis patients without known 
risk factors for infection (including 
HIV) during the past 5 years was also 
higher in the West (53%) compared 
with other regions (Table).
Most (93%) respondents reported 
that they were aware of the C. gattii 
outbreak. However, only 63% of 
respondents consider Cryptococcus 
species a factor of interest during 
diagnosis or treatment, and 54% would 
consider C. gattii as a differential 
diagnosis for pneumonia in a patient 
from the PNW. Although awareness 
of C. gattii appears high, recognition 
of infection may be delayed when 
diagnostic plans do not include species 
identifi cation.
Of the respondents, 94% 
reported that they most often use the 
cryptococcal antigen test for diagnosis, 
although 73% of respondents report 
that they commonly request a culture. 
Furthermore, 76 (27%) of respondents 
report using a combination of tests 
(cryptococcal antigen, microscopy, 
histopathology) that does not include 
culture. Tests that do not differen-
tiate between cryptococcal species 
represent missed opportunities for 
diagnosis of C. gattii infections. 
When respondents were asked if their 
clinical laboratory could differentiate 
C. neoformans from C. gattii isolates, 
131 (46%) responded “yes, either 
routinely or when requested”; 68 
(24%) responded “no”; 87 (30%) 
did not know. When we excluded 
respondents who did not know, only 
66% of respondents from the West 
indicated that their laboratory could 
differentiate species. This fi nding 
is concerning because outbreak-
associated C. gattii is clearly endemic 
to the region. A better understanding 
of which laboratories perform this 
service and which send specimens 
to a reference laboratory will help 
identify where additional capacity is 
needed.
A lower percentage of 
respondents from the Northeast 
(10%), Midwest (5%), and South 
(3%), compared with those from 
the West (44%), reported having 
ever consulted on a case of C. gattii 
infection. This may refl ect a low 
incidence of C. gattii infections in 
these regions, or it may be a result 
of decreased clinical suspicion for C. 
gattii infections outside the PNW.
Results from this study suggest 
that although most EIN members are 
aware of C. gattii and the ongoing 
outbreak in the PNW, missed 
opportunities for diagnosis still exist. 
To understand the true incidence 
of C. gattii inside and outside the 
PNW, vigilance among physicians 
nationwide is necessary. Clinicians and 
laboratorians should be aware of the 
need to obtain specimens for culture 
and of the need to develop methods to 
differentiate cryptococcal species. An 
accurate diagnosis of cryptococcosis 
cases in the United States will lead 
to a better understanding of the 
epidemiology and incidence of C. 
gattii in this country and may result in 
improved treatment.
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Coccidioidal 
Endophthalmitis in 
Immunocompetent 
Person, California, 
USA
To the Editor: In the United 
States, dimorphic fungi of the 
species Coccidioides are endemic to 
California (particularly the Central 
Valley), southern Arizona, southern 
New Mexico, and western Texas. 
Although there are a relatively large 
number of coccidioidomycosis cases 
in the United States (≈150,000/year), 
intraocular coccidioidomycosis is 
uncommon (1,2). We report a case 
of coccidioidal endophthalmitis in an 
immunocompetent person.
In October 2010, a 55-year-old 
white man in Santa Clarita, California, 
had severe pneumonia, drenching 
sweats, and an associated 25-pound 
weight loss. Three weeks later, when 
his symptoms had nearly resolved, 
the man reported having scratched 
his left eye with his eyeglasses and 
subsequent development of increasing 
redness, pain, and progressive vision 
loss (from 20/10 to 20/60 without 
correction).
In November 2010, the man 
sought the care of an ophthalmologist, 
who noted panuveitis of the left eye. 
Laboratory testing was performed: the 
erythrocyte sedimentation rate was 
49 mm/h (reference 0–22 mm/h), and 
test results were negative for human 
leukocyte antigen B27, angiotensin-
converting enzyme, rapid plasma 
reagin, and antinuclear antibody. 
The patient was started on topical 
corticosteroids and escalated to high-
dose prednisone soon thereafter 
without improvement. Pain continued 
to increase in his left eye, and visual 
acuity declined to hand motion only. 
Thus, in February 2011, the patient 
was referred to our institution, where 
an ocular ultrasound showed vitreous 
opacities (Figure). He underwent 
vitrectomy with intravitreal injection 
of empiric antimicrobial drugs, 
including voriconazole. Aqueous 
fl uid obtained intraoperatively grew 
mold, and the patient was admitted to 
the hospital for systemic antifungal 
therapy.
The patient’s history was 
unremarkable except for avid mountain 
biking in the Central Valley of 
California. His physical examination 
was notable for left visual acuity 
limited to hand motion only, limited 
extraocular movement, conjunctival 
injection, and hypopyon. His HIV 
test result was negative. Computed 
tomography (CT) scanning of the 
chest showed micronodules in the 
right upper lobe, suggesting previous 
pulmonary coccidioidal infection. 
Intravenous voriconazole (4 mg/kg 
every 12 hours) was administered 
along with daily intravitreal 
injections of voriconazole while the 
patient was hospitalized. Results for 
coccidioidal antibody testing were 
positive by enzyme immunoassay 
and immunodiffusion but negative by 
serum complement fi xation. Nucleic 
acid hybridization testing of aqueous 
fl uid cultures identifi ed Coccidioides 
spp. Results of a CT brain scan, lumbar 
puncture, and bone scan were normal. 
After 1 week of hospitalization, 
the patient was discharged on oral 
voriconazole (4 mg/kg 2×/day). 
Because of transaminitis, the patient 
was transitioned to fl uconazole (800 
mg/day) 4 weeks later. He underwent 
13 subsequent intravitreal injections 
of amphotericin and voriconazole. 
Eleven months after discharge, the 
patient’s best-corrected visual acuity 
was 20/25, and his ocular media were 
clear and without any lesions.
Coccidioidomycosis often 
goes undetected because up to 
60% of affected patients are 
asymptomatic (3). When signs and 
symptoms are present, they vary 
from subclinical infection to acute 
pneumonia to disseminated disease 
(3). The rate of extrapulmonary 
complications is estimated at 0.5% 
of infections in white persons, but 
such complications may occur in 
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Figure. Ocular ultrasound demonstrating hyperechoic, punctate opacities (arrows) within 
the vitreous chamber (X) of a patient with coccidioidomycosis, California, USA.
